🎯
LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$IFRX
InflaRx NV
UNITED STATESFREE PREVIEW
AVG HISTORICAL GAP2.52%
MAX GAP RECORD43.90%
PREMIUM
AI ACCURACY RATE92.4%
Unlock AI Insights 🔓LAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $IFRX
EXECUTIONS0
WIN RATE••.•%
NET ROI+•••.••%
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| RADAR SCANNING: WAITING FOR NEXT CATALYST | ||||||
🔒 Institutional Data Protected
UNLOCK FULL BLOTTERExact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
AVG VOLATILITY10.5%
Bullish Gaps
Bearish Gaps
Neutral
Intelligence Brief
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. Its primary product candidate is Vilobelimab. The company was founded by Niels Christoph Riedemann, Renfeng Guo, and Nicolas Fulpius in December 2007 and is headquartered in Jena, Germany. Read full dossier
CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL